Use of typical in-patient blood pressure measurements to detect bevacizumab-induced elevation in systolic pressure after the first infusion. Background: VEGFR-3 is a tyrosine kinase receptor ...

In a landmark study published in Current Molecular Pharmacology, a team led by Dr. Zhen Zhang from Central South University has identified six pivotal signaling pathways driving osteosarcoma ...

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...

Inhibition of tumor angiogenesis is a universal approach for the treatment of tumors. This calls for the development of more effective next-generation anti-angiogenic drugs for advancing the treatment ...

With multiple VEGFR-targeted therapies available after progression on immunotherapy-based regimens, oncologists continue to ...